Secondary Stock OfferingsBy The Online Investor Staff, updated Fri., Jan. 24, 5:14 PM
|This Slide: #3 of 25|
Slide #3. Misonix, Inc. — Secondary Offering
Misonix, Inc. (NASDAQ:MSON)
Date of Pricing:
Price Per Share:
Secondary Offering Details:
Misonix, Inc. (Nasdaq: MSON) ("Misonix" or the "Company"), a provider of minimally invasive therapeutic ultrasonic medical devices and regenerative products that enhance clinical outcomes, today announced that it has commenced an underwritten public offering of its common stock. In connection with the offering, Misonix intends to grant the underwriters an option, exercisable for 30 days after the date of the final prospectus supplement, to purchase up to an additional 15% of the shares of its common stock offered in the public offering on the same terms and conditions. -updated 1/23- Misonix, Inc. (Nasdaq: MSON) ("Misonix" or the "Company"), a provider of minimally invasive therapeutic ultrasonic medical devices and regenerative products that enhance clinical outcomes, today announced the pricing of an underwritten public offering of 1,625,000 shares of its common stock at a price to the public of $18.50 per share. The gross proceeds from this offering are expected to be $30 million, before deducting underwriting discounts and commissions, and offering expenses payable by Misonix. The offering is expected to close on or about January 27, 2020, subject to customary closing conditions. In addition, Misonix has granted the underwriters a 30-day option to purchase up to an additional 243,750 shares of its common stock on the same terms and conditions.
Misonix designs, manufactures and markets minimally invasive therapeutic ultrasonic medical devices. These products include the BoneScalpel® surgical system, which is used for surgical procedures involving the cutting of bone while sparing soft tissue; the SonaStar® Surgical Aspirator, which is used to emulsify and remove soft and hard tumors, primarily in the neuro and general surgery field; and the SonicOne® Wound Cleansing and Debridement System, which provides tissue debridement and cleansing of wounds and burns for removal of devitalized tissue and fibrin deposits while sparing viable cells.
MSON SEC Filing Email Alerts Service
Open the MSON Page at The Online Investor »
Strong Buy (4.00 out of 4)
(ranked higher than approx. 87% of all stocks covered)
Based on Zacks ABR data;
powered by Xignite